Vaccine Updates – Pfizer
Recently, Pfizer communicated some changes to their vaccine portfolio. The addition of Pfizer’s Penbraya™, a new pentavalent meningococcal vaccine, FDA approved and ACIP recommended as an option when both MenACWY and MenB are indicated at the same visit.
For CPP members, the new pricing goes into effect on February 28, 2024. For details and updated pricing sheets, CPP members can contact the CPP office at 614-722-2145 or cpp@nationwidechildrens.org. If your practice is not yet linked to CPP through the Pfizer portal and still paying list price for these vaccines, contact the CPP office for detailed instructions for how to enroll.
We expect that private payers will be working to incorporate Penbraya™ into their payment schedules in the coming months and recommend that you reach out to your major payers to verify adequate payment is in place for this new CPT code.
CPP has also updated its Pediatric and Adult coding cheat sheets to include the new code.
CPP Resources
Vaccine manufacturers typically increase pricing on vaccines annually. Vaccines are expensive and price increases give an opportunity to check the financial health of your practices’ vaccine administration program. Below are a few resources that should help you navigate these price changes.
